Closing Remarks on Upcoming Data and Future Perspectives in MCL and CLL
September 15th 2022Looking to the future, a panel of experts offers closing remarks on research in CLL and MCL including hopes for further data on bispecific antibodies, BTK degraders, CAR T-cell therapy, and pirtobrutinib.
Read More
Anti-CD20 Regimens and Triplet Therapies in CLL
September 9th 2022Orienting the conversation around anti-CD20-drug-based combination and sequencing approaches, the panelists examine key takeaways from the CLL13 and CLL14 clinical trials as well as expectations for real-world data in the future.
Read More
Second-line Therapies in MCL: Regimens With BTK Inhibitors and BCL-2 Targeting Therapies
July 22nd 2022Key opinion leaders in mantle cell lymphoma discuss the emergence of more effective novel therapies such as BTK inhibitors and BCL-2 inhibitors and whether there is a continued role for lenalidomide-based regimens.
Read More
Frontline Therapy for CLL: Treatment Selection Based on Patient and Treatment Factors
February 7th 2022Variables that impact which Bruton tyrosine kinase inhibitor is most appropriate as frontline therapy for patients with newly diagnosed chronic lymphocytic leukemia and the role of patient and disease factors in treatment selection.
Read More